4D Molecular Therapeutics, Inc.: BIOTECHNOLOGY VALUE FUND L P amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Biotechnology Value Fund L.P. filed an amended Schedule 13G with the SEC (accession 0000921895-26-003177) updating its beneficial ownership stake in 4D Molecular Therapeutics, Inc. The filing signals a change in the institutional investor's position in the clinical-stage gene therapy developer. The amendment's details on the exact size and direction of the stake change were not disclosed in the headline. Investors will watch for the updated ownership percentage and any subsequent 13F or 13G filings for further clarity on the fund's conviction.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
4D Molecular Therapeutics, Inc., BIOTECHNOLOGY VALUE FUND L P